Press Releases October 2, 2026 09:43 AM

SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026

SeaStar Medical to present encouraging pediatric sepsis-associated AKI outcomes at ASN Kidney Week 2026

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
ICU

SeaStar Medical announced that data evaluating the post-approval SAVE Registry results for their FDA-approved QUELIMMUNE (SCD-PED) device will be presented as a late-breaking poster at ASN Kidney Week 2026. The company focuses on treatments for critically ill patients with organ failure, especially pediatric acute kidney injury (AKI) due to sepsis. Their selective cytopheretic device (SCD) has received multiple FDA Breakthrough Device Designations and is undergoing pivotal trials for adult AKI patients with limited treatment options.

SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026
ICU
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Late-breaking presentation of SAVE Registry data highlighting improved outcomes in pediatric sepsis-associated AKI at ASN Kidney Week 2026.
  • QUELIMMUNE (SCD-PED) is the only FDA-approved product for pediatric life-threatening AKI due to sepsis requiring renal replacement therapy.
  • SeaStar Medical's SCD therapy holds six FDA Breakthrough Device Designations and is undergoing pivotal clinical trials for adult AKI patients, addressing a critical unmet medical need.

DENVER, Oct. 02, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life announced today that a late-breaking abstract evaluating the results of the post-approval SAVE Registry data has been accepted for a special late-breaker poster presentation at the upcoming American Society of Nephrology (ASN) Kidney Week 2026 meeting, taking place in Denver, CO, October 21 – 25, 2026.

Presentation Details:

Title: Improved Outcomes in Pediatric Sepsis-Associated (SA) AKI: Comparison of the Selective Cytopheretic Device for Pediatrics (SCD-PED) Surveillance Registry (SAVE) with a Historical Cohort

Authors: Nathan L. Kleinman, Stuart Goldstein, Rajit K. Basu, Theresa A. Mottes, David J. Askenazi, Stephen Gorga, Shina Menon, Matt S. Zinter, Keri A. Drake, David A. Zolezzi, Robert S. Gillespie, Sai Prasad N. Iyer, Emily Scribe, Kevin K. Chung

Abstract / Poster Number: TH-PO1291

Date & Time: October 22, 2026, from 10:00 a.m. to 12:00 p.m. MT

Location: Exhibit Hall A, Colorado Convention Center

About SeaStar Medical

SeaStar Medical is a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. SeaStar Medical’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening Acute Kidney Injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT) in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting the NEUTRALIZE-AKI pivotal clinical trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.

For more information visit www.seastarmedical.com or visit us on LinkedIn or X.

Contact:  
[email protected]

QUELIMMUNE is a registered trademark of SeaStar Medical Holding Corporation.


Risks

  • Clinical trial outcomes for adult AKI pivotal trial (NEUTRALIZE-AKI) are still pending, which could impact future approvals and commercial viability.
  • Market adoption of QUELIMMUNE (SCD-PED) and reimbursement dynamics remain uncertain despite FDA approval and Breakthrough Device status.
  • The ultra-rare pediatric AKI market is limited in size, which could constrain revenue growth potential despite strong clinical data.

More from Press Releases

Sachem Capital Reports Third Quarter 2026 Results Nov 16, 2026 Inter&Co Delivers Record 3Q26 Net Income of US$76.1 Million, With Strong Growth, Higher Margin and Better Efficiency Nov 12, 2026 Super League to Report Third Quarter 2026 Financial Results on Monday, November 16, 2026 Nov 12, 2026 UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights Nov 4, 2026 BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules Nov 4, 2026